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Abstract 
Malaria currently causes more harm to human beings than any other parasitic disease, and disproportionally affects 
low‑income populations. The ethical issues raised by efforts to control or eliminate malaria have received little explicit 
analysis, in comparison with other major diseases of poverty. While some ethical issues associated with malaria are 
similar to those that have been the subject of debate in the context of other infectious diseases, malaria also raises 
distinct ethical issues in virtue of its unique history, epidemiology, and biology. This paper provides preliminary ethical 
analyses of the especially salient issues of: (i) global health justice, (ii) universal access to malaria control initiatives, (iii) 
multidrug resistance, including artemisinin‑based combination therapy (ACT) resistance, (iv) mandatory screening, (v) 
mass drug administration, (vi) benefits and risks of primaquine, and (vii) malaria in the context of blood donation and 
transfusion. Several ethical issues are also raised by past, present and future malaria research initiatives, in particular: (i) 
controlled infection studies, (ii) human landing catches, (iii) transmission‑blocking vaccines, and (iv) genetically‑mod‑
ified mosquitoes. This article maps the terrain of these major ethical issues surrounding malaria control and elimina‑
tion. Its objective is to motivate further research and discussion of ethical issues associated with malaria—and to assist 
health workers, researchers, and policy makers in pursuit of ethically sound malaria control practice and policy.
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provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Malaria morbidity and mortality are largely preventable 
via existing interventions (e.g., anti-malarial drugs, insec-
ticide, nets, and other vector control measures). There 
has been a significant increase in financial aid directed 
at malaria control in the last decade, resulting in a halv-
ing of global malaria burden since 2004 [1, 2]. However, 
of the approximately US $5.1 billion required for malaria 
control initiatives in 2013, only $2.8 (i.e., 55 %) was avail-
able from existing funding mechanisms (from individual 
countries and international sources combined) [3], mean-
ing that many people do not even benefit from the sim-
ple protection of inexpensive and cost-effective bed nets 
[1]. Furthermore, access to such interventions is often 
inversely proportional to wealth and proximity to major 
urban centres, and can be especially poor for mobile pop-
ulations at high risk of malaria [4, 5].
Programmes combatting other similarly impor-
tant infectious diseases, such as HIV and tuberculosis, 
raise many ethical issues that have been identified and 
addressed to some extent [6–8], yet malaria control, 
treatment and research have received comparatively lit-
tle explicit ethical analysis and debate. This article sum-
marizes the limited existing literature on ethical issues 
associated with malaria and highlights areas in need 
of further work. Though some scientists or health pro-
fessionals might have a narrow conception of ethics as 
a process of research review, ethics more generally is 
broadly concerned with questions about value, what 
actions ought to be taken, and what policy should be. 
Such questions partly turn on the aim to achieve good 
outcomes—such as maximal disease burden reduction–
but they also concern issues of justice and the moral obli-
gations of medical professionals and patients. With this 
in mind, this review maps the terrain of such issues in the 
context of malaria control, offers some preliminary anal-
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Epidemiology and justice
The prevalence of malaria is inversely proportional to 
GDP per capita. Sachs and Malaney aptly note that 
“where malaria prospers most, human societies have 
prospered least” [9]. Vulnerability to malaria, like many 
other infectious diseases, is largely a product of social 
determinants of health—such as poverty, malnutrition, 
and insufficient access to healthcare. Like HIV and other 
diseases of poverty, malaria is not only an effect of pov-
erty but also further impoverishes families and commu-
nities [9, 10].
International efforts towards malaria control thus rep-
resent a major opportunity to remedy some of the past 
and present injustices manifested by global disparities in 
wealth and freedom from preventable disease [11, 12]. 
Inter alia, justice requires both improvement of access to 
existing interventions and increased research and devel-
opment of new tools for malaria control, both of which 
require an influx of funding from wealthy nations and 
donor organisations. Malaria burden is a major exam-
ple of global inequities, which are receiving heightened 
attention at the international level as reflected by the Sus-
tainable Millennium Development Goals.
Climate change
Anthropogenic climate change affects human health in 
many ways, and has the potential to alter malaria disease 
patterns by changing the habitats of Anopheles mosqui-
toes, and by displacing human populations [13–15]. 
Areas potentially at increased risk of malaria include 
high altitude (>1,600  m) areas, especially in East Africa 
[16] and potentially temperate zones in central Asia, 
Europe and North America [17]. While future predic-
tions are necessarily uncertain, the multiple mechanisms 
by which climate influences malaria warrant further 
research. An increase in malaria burden due to climate 
change is also a matter of justice, since those who would 
suffer most are (usually/often) those who (1) are already 
among the worst-off groups of (global) society and (2) 
themselves contribute least to climate change. The nexus 
of climate and disease provides additional reasons to 
minimize climate change (to prevent disease spread), 
and conversely to intervene on malaria transmission in 
the present, since this will help mitigate any future rela-
tive increase in malaria risk due to climate change. Simi-
lar reasoning applies to the wide range of other diseases 
(including dengue) which may be influenced by the same 
mechanisms.
Access to malaria control and the rise of resistant malaria
A core ethical issue for malaria policy is the urgent 
need for universal access to control interventions [3, 
5]. With regards to prevention, the use of long-lasting 
insecticide-treated bed nets is a cost-effective way to 
reduce the disease burden of malaria in communities in 
endemic areas, although effectiveness varies by region 
and widespread coverage is needed for greatest benefit 
[18]. Since nets protect not only those who sleep under 
them but also the wider community by reducing trans-
mission, a community-level benefit is placed at risk when 
a significant proportion of families cannot afford even 
subsidized nets due to severe poverty. Everyone nearby 
benefits when all have access to nets, thus there is a 
moral imperative that bed nets (like many vaccines) are 
universally available and, where necessary, free of charge 
[19, 20].
The cost of anti-malarial medications poses similar 
challenges, and lack of access to adequate health services 
commonly leads to treatment failure and death. Counter-
feit drugs, for example, may be more widely available in 
areas with limited healthcare infrastructure [21]. In addi-
tion to having direct adverse effects on patients, counter-
feit drugs contribute to the emergence of drug resistance 
[22].
Overall the lack of access to prevention and treatment 
for the most impoverished or isolated will only increase 
the injustices associated with malaria. Universal cover-
age that is free or genuinely affordable will be the only 
way to sustainably control or eradicate the disease. It will 
also have secondary benefits such as decreasing pressure 
on hospitals by reducing the total incidence of severe 
malaria, and by preventing the emergence and spread of 
resistance.
Anti‑malarial resistance
Anti-malarial resistance, especially to artemisinin-based 
combination therapy (ACT), is a major threat to malaria 
control efforts. Resistance generally results from inap-
propriate, incomplete or inadequate courses of treat-
ment. This most commonly occurs in the context of 
poverty, counterfeit medications, and weak healthcare 
infrastructure [1, 23]. The major early ‘hotspots’ for 
ACT resistance were clustered around national border 
zones in the Greater Mekong sub-region of South East 
Asia. The presence of impoverished, mobile and politi-
cally marginalized populations, including large numbers 
of refugees, are likely contributors to this phenome-
non [24, 25]. As with drug resistance in other diseases, 
political and socioeconomic factors are clear drivers of 
anti-malarial resistance, which is thus an issue of inter-
national justice. In addition, wealthy countries should 
be concerned about anti-malarial resistance for self-
interested reasons, as (i) resistant strains of malaria may 
spread beyond the borders of poor countries and (ii) the 
economic costs of control efforts will rise with increas-
ing resistance.
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The current ethical priorities to address drug resist-
ance are therefore: universal availability of (i) diagnos-
tic support (including resistance testing), (ii) targeted, 
locally effective treatments, before multi-resistant strains 
emerge, and (iii) increased research and development of 
new drugs (to combat multi-resistant strains). Universal 
access to these resources would significantly address cur-
rent injustices, and help to prevent major future harms 
and increased costs due to resistance.
Individual and public health interests
Several malaria control strategies have specific ethical 
implications. The following sections address some exam-
ples that require the balancing of individual liberties 
against public health goals.
Mandatory screening
Mandatory screening has been implemented in many 
countries targeting or maintaining malaria elimination. 
This involves the compulsory testing of asymptomatic 
travellers or immigrants from malaria endemic zones 
[26, 27]. There is a strong ethical rationale for manda-
tory screening for malaria in such circumstances. First, 
the individual being screened stands to benefit from 
treatment if infected. Second, significant public health 
risks may be averted by preventing new outbreaks [28]. 
Importantly, the minimal limitations on individual lib-
erty imposed by mandatory screening should be weighed 
against the significant individual and community 
benefits.
Resistant malaria creates a further justification for 
mandatory screening e.g., to prevent the spread of ACT-
resistance from South East Asia to India and Africa [29]: 
a recent example is the screening of Cambodian peace-
keeping troops in 2014 before deployment to Mali. In 
all cases, a clear ethical framework should be developed 
to inform screening programmes, and the testing used 
should be chosen with care. The number of irregu-
lar migrants and refugees from endemic countries can 
increase the practical and ethical complexity of such poli-
cies [30]; implementation should aim at benefits for both 
migrants and local communities, without creating undue 
restrictions, discrimination, or stigma for those from 
high prevalence areas [31].
Mass drug administration
At present, the circumstances in which mass drug admin-
istration (MDA) would provide a cost-effective long-term 
benefit have yet to be clearly defined, but it could play 
an important role in eradication efforts [32]. Ethically, it 
is important to consider the fair distribution of benefits 
and burdens, noting that infected individuals will receive 
the greatest immediate benefits while all (including those 
not infected) may share the risks and burdens of treat-
ment, including increased resistance where MDA does 
not achieve elimination. Individual and community ben-
efit would be highest in seasonal prophylaxis, although 
there are potential issues with delaying natural immunity, 
and thus a rebound in incidence and severity. Conversely, 
elimination efforts may be most effectively targeted at 
populations and times with relatively low levels of para-
sitaemia, where the balance of risks and benefits requires 
careful consideration, noting the benefits of elimination 
to both current and future generations.
In all cases, communities should be closely involved 
in programme design. If mass screening is used prior to 
MDA, the test should be chosen based on programme 
goals and community acceptability where feasible, some 
form of informed consent at the community and/or 
individual level should be coupled with well-designed 
education and social awareness campaigns to ensure 
population-wide effectiveness [33].
Primaquine
The aminoquinolones (primarily primaquine) present a 
unique ethical case in malaria control. The use of such 
drugs is one of the few ethical issues specific to malaria 
that has received explicit ethical analysis [34]. When used 
in low-doses as a gametocidal agent for Plasmodium fal-
ciparum, primaquine is safe and largely effective [35], yet 
higher doses used in anti-relapse therapy for Plasmo-
dium vivax carry higher risks. While treatment-related 
deaths are rare, the risks of haemolysis conferred by dif-
ferent genotypes and phenotypes in different populations 
have not been well defined, and no point-of-care test can 
determine individual risk. This poses practical as well as 
ethical challenges for clinicians and policy makers, espe-
cially where primaquine is considered in P. vivax elimina-
tion MDA including aparasitaemic individuals, for whom 
the ratio of risks to benefits would be highest [34].
Alternative agents are needed for those who cannot 
take primaquine, including pregnant women [34]. In 
the absence of alternatives, appropriate treatment with 
primaquine must continue, especially in regions with a 
high burden of P. vivax. Meanwhile, the moral priorities 
to adequately inform patients and reduce overall harms 
where possible should guide further research aimed at 
improving treatment programmes. Thus, ultimate goals 
of research in this area should be development of (i) accu-
rate point-of-care testing for risk of haemolysis (G6PD 
deficiency) and (ii) less toxic alternatives to primaquine. 
Current efforts should meanwhile include (i) epidemio-
logical mapping of G6PD deficiency traits in regions aim-
ing at elimination, (ii) further elucidation of phenotypic 
risk in different genotypes of G6PD deficiency, and (iii) 
primaquine dose-finding studies [34, 36–38].
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Blood donation and transfusion
Malaria was one of the first recorded transfusion-trans-
mitted infections [39]. Although the burden and risk of 
transfusion-transmitted malaria is low in comparison to 
infections such as HIV and viral hepatitis [40], the issue 
of transfusion-transmitted malaria has been largely over-
looked. This has resulted in inconsistent practices and 
policies regarding donor screening, disclosure of disease 
status, and provision of treatment or preventative meas-
ures to donors and recipients [41]. For instance, in some 
areas all blood donors are screened for malaria whereas, 
in others, treating all blood donors with anti-malarials 
is common practice [39]. Ethical analysis of benefits 
and risks should underpin the development of relevant 
guidelines. For example, robust disclosure and treatment 
mechanisms should be put in place to benefit asympto-
matic donors who are diagnosed with malaria via blood 
screening [42].
Ethical issues in malaria research
Controlled infection studies
Controlled infection studies involve intentionally 
exposing human beings to pathogens in order to 
observe the natural history of disease, develop research 
models of infection, or test the efficacy of drugs and 
vaccines [43]. Modern studies in controlled malaria 
infection date to 1900 [44] and continued during World 
War II [45, 46]. Current studies are performed safely, 
with no deaths or lasting symptoms among participants 
[47]. However, participants often experience signifi-
cant acute symptoms—including fever, headache, joint 
and muscle pains, and even cardiac events—which 
go beyond many definitions of ‘minimal harm’ that 
are commonly employed in the ethical assessment of 
non-therapeutic research [43]. Further, malaria infec-
tion studies often involve exposure to blood products 
via mosquitoes or injection [48], which poses the risk 
of transmitting other infections and prion diseases. 
Finally, if participants are able to leave research cen-
tres while still infected, this can pose risks to the wider 
community. In all cases, participants must be carefully 
selected and informed.
Yet such studies remain important in testing new vac-
cines or treatments, and it may be more useful to perform 
them in malaria endemic populations. Risks of controlled 
infection studies may be somewhat less for participants 
with substantial immunity from prior infection, and the 
benefits of participation may also be greater (e.g., in the 
case of studies testing new vaccines). On the other hand, 
such studies should only occur in contexts with access to 
affordable quality healthcare, high standards of research 
conduct, and robust ethical oversight so that the safety of 
participants is ensured [49].
Human landing catches
Malaria research to measure mosquito or malaria den-
sity has often involved the use of human landing catches, 
where human participants act as mosquito ‘traps’. In 
some cases, people working as human landing catches 
may receive 50–100 mosquito bites in one nightshift [50]. 
The use of human landing catches poses similar ethical 
issues to those raised by controlled infection studies, 
where potential harms to a few individuals are (volun-
tarily consented to and) balanced against benefits to the 
wider community. In practice, the absolute harm appears 
to be low, since people undertaking this kind of work are 
provided with a high standard of diagnosis and treatment 
[43, 47]. These studies have provided essential insights 
into the biology and transmission of malaria that may 
not have been feasibly obtained by other means. It would 
nonetheless be ethically preferable to develop alterna-
tive practices that offer no risk to human beings. In this 
context, trials of novel mosquito traps [51] are a welcome 
development, though human landing catches remain a 
‘gold standard’ against which these traps are tested [52].
Transmission‑blocking vaccines
Ethical issues related to vaccination have been discussed 
for other diseases [53, 54], and should be considered 
in both the investigation and eventual implementa-
tion of malaria vaccines. For example, the success of the 
RTS,S vaccine (45  % vaccine efficacy in children aged 
5–17 months and 34 % in infants, with some protection 
against severe malaria in children but not infants [55]) 
raises the question of what trials of other vaccines should 
use as an ethically acceptable control arm (placebo or 
RTS,S). Requirements such as those of the Declaration of 
Helsinki that all new agents be tested against the stand-
ard of care are controversial in this context and, with 
careful consideration, an argument could be made to 
support using placebo despite the existence of a partially 
effective vaccine [56].
The avenue of transmission-blocking vaccines (TBVs) is a 
novel case study in vaccine ethics, especially since they aim 
only at preventing transmission of malaria from the vacci-
nated person to healthy individuals [49]. Though there are 
indirect self-interested reasons to be vaccinated (protecting 
one’s family and reducing intra-household transmission), 
individuals would primarily be administered a TBV in 
order to create effective herd protection. Importantly, herd 
protection also extends to those who do not respond to, or 
cannot safely receive, vaccines, and is the main mechanism 
by which such individuals can benefit from vaccination 
[53]. In such cases a substantial majority of the population 
needs to be vaccinated, and ethical approaches to collective 
vaccination have been published elsewhere [54]. Where 
the vaccine is proven to be safe and effective and the public 
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health goal is sufficiently important (e.g., the eradication 
of malaria), there are likely to be strong ethical grounds 
for universal vaccination. Thus, effective vaccination infra-
structure covering the entire target population as well as 
education and social campaigns to ensure high levels of 
uptake would be of paramount importance in any even-
tual implementation of TBVs. Meanwhile, TBV researchers 
should consider whether to co-administer other interven-
tions (perhaps even other vaccines) with TBVs in trial set-
tings in order to optimize individual benefit.
Genetically‑modified (GM) mosquitoes
Multiple strategies for genetic modification of mosqui-
toes are under study, aiming to contribute to transmis-
sion interruption for malaria (and other mosquito-borne 
diseases) [57–59]. Implementation of such strategies 
depends both on adequate scientific development and 
acceptance of local communities. Currently, the eco-
logical consequences of GM mosquitoes are poorly 
understood [60]. Although risks will vary with different 
techniques, they would often be difficult to control once 
such insects were released. This raises ethical questions 
about how to balance potential significant improvements 
in population health against possible environmental 
harms, and whether other interventions with fewer risks 
would be preferable. Where multiple GM techniques are 
available, the relative risks of each should be considered. 
Policies regarding the use of GM mosquitoes should be 
informed by ethical analysis and prospective consulta-
tion at the level of research groups, local communities, 
national governments and international organisations. 
Groups planning to release GM mosquitoes have the 
strongest obligations towards communities who will be 
most affected, and strategies to ensure responsible prac-
tice have been published by WHO [61].
Conclusions
Ethical issues in malaria control and research have hith-
erto received little explicit analysis in the published lit-
erature. This review provides an initial summary of the 
main issues at hand, but further work is required in many 
of the areas discussed above, especially since the field is 
likely to evolve with future changes in malaria science, 
epidemiology and policy.
The epidemiology of malaria is a stark reminder of 
global injustice in relation to disease risk and health out-
comes. The recent improvements in funding and control 
initiatives have in part been driven by an awareness of 
these injustices: that those least able to access malaria 
control mechanisms are often those who need them 
most, and that there are significant research gaps for 
malaria and other diseases of poverty. Similarly, ethics 
can help to guide policy and treatment in areas such as 
the control of anti-malarial resistance, mass screening 
and treatment programmes, and the use of primaquine. 
In malaria research, specific ethics guidelines should be 
developed to ensure valuable research programmes con-
tinue without imposing excessive risks on participants. 
Looking toward future possibilities, prospective con-
sideration of ethical issues may assist in the appropriate 
and successful implementation of novel techniques such 
as malaria vaccines or genetically-modified mosquitoes. 
Recent capacity building efforts for local ethics expertise 
in endemic regions have been a positive development.
The preliminary analyses offered here are intended to 
motivate further research on ethical issues associated 
with malaria, inform ethics review processes related 
to control interventions, and assist health workers, 
researchers, and policy-makers in pursuit of ethically 
sound malaria control efforts. The ultimate beneficiar-
ies of such work will include patients and residents of 
malaria endemic areas who are in the greatest need of 
ethically designed malaria programmes now and in the 
coming decades.
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